viewTesla Inc

Roth reiterates Neutral rating for Tesla after disappointing 1Q delivery numbers

Shares of the electric-car maker rose Friday, making back some of the ground it lost

White Tesla car
The firm was alarmed by Tesla’s 12,100 first-quarter Model S and Model X delivery numbers, less than half than the quarter before.

Roth Capital Partners reiterated its rating and price target for Tesla (NASDAQ:TSLA) Thursday – right after the electric carmaker’s stock fell more than 8% on disappointing first-quarter delivery numbers.

Roth stuck to its Neutral rating and $270 price target for the Pala Alto, California company.

Shares were up 2.7% Friday to $274.96.

The firm was particularly alarmed by Tesla’s 12,100 Model S and Model X delivery numbers, a drop to less than half of the 27,600 in the quarter before.

READ: Tesla plunges in New York as it posts biggest sales drop in its history

“Tesla’s cars are just too expensive for the niche of the market they are chasing,” Roth analysts wrote.

Also concerning was Tesla’s lack of advantage on battery costs. According to METI data, Japan automotive Lithium ion cells price at $240 per kilowatt hour. Tesla buys 80% of its batteries, Roth wrote, which makes Tesla’s estimate of battery costs between $100 and $150 per kilowatt hour seem laughable.

The analyst correctly predicted that no major action was likely to come of CEO Elon Musk’s contempt court hearing. On Thursday, Judge Allison Nathan gave Musk and the SEC two weeks to work out their differences. The SEC wanted to hold Musk in contempt for Tweeting without company approval in violation of their fraud agreement.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Tesla Inc

Price: 454.47 USD

Market: NASDAQ
Market Cap: $83.8 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: BioCorRx says COVID-19 will not delay their work on...

BioCorRx (OTCMKTS: BICX) CEO Brady Granier joined Steve Darling from Proactive in Vancouver to discuss if their business and research are being affected by the outbreak of COVID-19. Granier telling Proactive some of the ways the company is able to continue their works especially when it...

10 hours, 34 minutes ago

2 min read